Veterinary medicines European public assessment report (EPAR): Varenzin, molidustat, Status: Authorised
Veterinary medicines European public assessment report (EPAR): Varenzin, molidustat, Status: Authorised
Veterinary medicines European public assessment report (EPAR): Varenzin, molidustat, Status: Authorised
Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Date of authorisation: 18/02/2021, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, Date of authorisation: 21/06/2018, Revision: 19, Status: Authorised
Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Date of authorisation: 29/06/2004, Revision: 35, Status: Authorised
Human medicines European public assessment report (EPAR): Leflunomide Zentiva (previously Leflunomide Winthrop), leflunomide, Date of authorisation: 08/01/2010, Revision: 23, Status: Authorised
Emerging safety issues (ESI) contact points at the national competent authority (NCA) level
Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 9, Status: Authorised
HMA-EMA Network Data Steering Group: membership list
HMA-EMA joint Network Data Steering Group meeting - 8 December 2025
Human medicines European public assessment report (EPAR): Pomalidomide Teva, pomalidomide, Date of authorisation: 14/11/2024, Revision: 1, Status: Authorised